Merus N.V., a clinical-stage oncology company, is set to participate in the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3. The company, known for developing innovative multispecific antibodies and antibody-drug conjugates, will have its President and CEO, Dr. Bill Lundberg, present at the event. The presentation will be webcast live on the company's investor website and available for a limited time afterwards.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。